Evidence map›Paper›PMID 29684021›Full record

ArticlePLoS neglected tropical diseases2018

Laboratory and molecular surveillance of paediatric typhoidal Salmonella in Nepal: Antimicrobial resistance and implications for vaccine policy.

Carl D Britto, Zoe A Dyson, Sebastian Duchene, Michael J Carter, Meeru Gurung, Dominic F Kelly, David R Murdoch, Imran Ansari, Stephen Thorson, Shrijana Shrestha and 4 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A systematic review of antimicrobial resistance of typhoidalThe Indian journal of medical research · 2019
    Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Comparative genomics ofVirulence · 2025
    Article
  9. A contemporary genomic snapshot ofMicrobial genomics · 2025
    Article
  10. Article
  11. Genetic heterogeneity in theMicrobial genomics · 2024
    Article
  12. Article
  13. Typhoid fever.Nature reviews. Disease primers · 2023
    Review
  14. Article
  15. Genomic Surveillance ofOpen forum infectious diseases · 2023
    Article
  16. Frontiers in microbiology · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Carl D BrittoOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.ORCID 0000-0002-1674-8801
Zoe A DysonDepartment of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-8887-3492
Sebastian DucheneDepartment of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.
Michael J CarterOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.ORCID 0000-0003-3403-4746
Meeru GurungOxford University Clinical Research Unit-Patan Academy of Health Sciences, Patan, Nepal.ORCID 0000-0003-4366-6403
Dominic F KellyOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
David R MurdochUniversity of Otago, Christchurch, New Zealand.
Imran AnsariOxford University Clinical Research Unit-Patan Academy of Health Sciences, Patan, Nepal.
Stephen ThorsonOxford University Clinical Research Unit-Patan Academy of Health Sciences, Patan, Nepal.ORCID 0000-0002-9546-6406
Shrijana ShresthaOxford University Clinical Research Unit-Patan Academy of Health Sciences, Patan, Nepal.
Neelam AdhikariOxford University Clinical Research Unit-Patan Academy of Health Sciences, Patan, Nepal.
Gordon DouganWellcome Trust Sanger Institute and the Department of Medicine, Cambridge University, Cambridge, United Kingdom.
Kathryn E HoltDepartment of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-3949-2471
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Patan Academy of Health Sciences · NPUniversity of Oxford · GBThe University of Melbourne · AUUniversity of Cambridge · GBUniversity of Otago · NZ

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundChildren are substantially affected by enteric fever in most settings with a high burden of the disease, including Nepal. However pathogen population structure and transmission dynamics are poorly delineated in young children, the proposed target group for immunization programs. Here we present whole genome sequencing and antimicrobial susceptibility data on 198 S. Typhi and 66 S. Paratyphi A isolated from children aged 2 months to 15 years of age during blood culture surveillance at Patan Hospital, Nepal, 2008-2016. PRINCIPAL

findingsS. Typhi was the dominant agent and comprised several distinct genotypes, dominated by 4.3.1 (H58). The heterogeneity of genotypes in children under five was reduced compared to data from 2005-2006, attributable to ongoing clonal expansion of H58. Most isolates (86%) were non-susceptible to fluoroquinolones, associated mainly with S. Typhi H58 lineage II and S. Paratyphi A harbouring mutations in the quinolone resistance-determining region (QRDR); non-susceptible strains from these groups accounted for 50% and 25% of all isolates. Multi-drug resistance (MDR) was rare (3.5% of S. Typhi, 0 S. Paratyphi A) and restricted to chromosomal insertions of resistance genes in H58 lineage I strains. Temporal analyses revealed a shift in dominance from H58 Lineage I to H58 Lineage II, with the latter being significantly more common after 2010. Comparison to global data sets showed the local S. Typhi and S. Paratyphi A strains had close genetic relatives in other South Asian countries, indicating regional strain circulation. Multiple imports from India of ciprofloxacin-resistant H58 lineage II strains were identified, but these were rare and showed no evidence of clonal replacement of local S. Typhi. SIGNIFICANCE: These data indicate that enteric fever in Nepal continues to be a major public health issue with ongoing inter- and intra-country transmission, and highlights the need for regional coordination of intervention strategies. The absence of a S. Paratyphi A vaccine is cause for concern, given its prevalence as a fluoroquinolone resistant enteric fever agent in this setting.

Indexed as

Drug Resistance, BacterialTyphoid-Paratyphoid VaccinesAdolescentAnti-Infective AgentsChildChild, PreschoolCiprofloxacinFemaleFluoroquinolonesGenotypeHumansInfantMaleNepalSalmonella typhiTyphoid FeverAnti-Infective AgentsCiprofloxacinFluoroquinolonesTyphoid-Paratyphoid Vaccines

Identifiers

PMID29684021
PMCPMC5933809
OpenAlexW2793412178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.